Founded in 1996, Neuralstem focuses on creating human neural stem cell technologies to treat diseases of the central nervous system, such as ALS, Parkinson's, and spinal cord injuries. Their lead therapy candidate, NSI-566, is in clinical testing for ALS, chronic spinal cord injury, and ischemic stroke. They also have a product candidate, NSI-189, in development for major depressive disorder and other conditions. Neuralstem aims to commercialize their treatments and has completed Phase II clinical studies in China for ischemic strokes. Additionally, they acquire assets to improve therapeutic technologies and offer global licensing of monoclonal antibodies for autoimmune diseases.